Dicot Pharma

0.673

SEK

+18.49 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+18.49%

+109.01%

+145.17%

+177.53%

+201.79%

+232.75%

+291.25%

-2.68%

-73.67%

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.

Market cap

1.35B SEK

Turnover

23.35M SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

11.8

2025

Interim report Q2'25

22.10

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press release5/28/2025, 6:40 AM

Dicot Pharma AB: Dicot Pharma's new findings on mechanism of action: "affects the nerves controlling penile erection"

Regulatory press release5/6/2025, 4:54 PM

Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma

Regulatory press release4/29/2025, 6:15 AM

Dicot Pharma AB: Dicot Pharma presents interim report Q1 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/3/2025, 7:00 AM

Dicot Pharma AB: Summon to Annual General Meeting in Dicot Pharma May 6 at 17.00

Regulatory press release4/2/2025, 6:30 AM

Dicot Pharma AB: Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Last day of trading in Dicot Pharma TO 6 warrants tomorrow, March 27

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma invites to a Q&A session on TO 6

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma's TO 6, Running Until March 31, 2025

Regulatory press release3/11/2025, 7:30 AM

Dicot Pharma AB: Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

Press release2/26/2025, 11:39 AM

Dicot Pharma AB: Professor after ESSM: "The interest in Dicot Pharma's work continues to grow"

Regulatory press release2/13/2025, 7:25 AM

Dicot Pharma AB Year-End Report 2024

Press release2/5/2025, 9:40 AM

Dicot Pharma AB: Half of the participants now dosed in Dicot Pharma's Phase 2a study

Regulatory press release12/19/2024, 9:11 AM

Dicot Pharma AB: Entire Patent Family Reaching Approval in the United States

Press release12/17/2024, 2:17 PM

Dicot Pharma AB: French Expert to Present Results from Dicot Pharma at ESSM

Regulatory press release11/26/2024, 2:33 PM

Dicot Pharma AB: Dicot Pharma granted new patent in the USA

Regulatory press release11/20/2024, 6:00 AM

Dicot Pharma AB: First participants dosed in Dicot Pharma's Phase 2a clinical study

Press release11/19/2024, 2:53 PM

Dicot Pharma AB: International business development expert joins Dicot Pharma

Regulatory press release11/8/2024, 9:17 AM

Dicot Pharma AB: Dicot Pharma announces initiation of Phase 2a clinical study

Regulatory press release11/6/2024, 2:43 PM

Dicot Pharma AB: Dicot Pharma listed on Nasdaq First North

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.